ES2152953T3 - Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina. - Google Patents

Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina.

Info

Publication number
ES2152953T3
ES2152953T3 ES93921129T ES93921129T ES2152953T3 ES 2152953 T3 ES2152953 T3 ES 2152953T3 ES 93921129 T ES93921129 T ES 93921129T ES 93921129 T ES93921129 T ES 93921129T ES 2152953 T3 ES2152953 T3 ES 2152953T3
Authority
ES
Spain
Prior art keywords
protein
hemostatic
specific antibodies
intact proteins
compounds lack
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93921129T
Other languages
English (en)
Inventor
Koenraad Mertens
Mourik Jan Aart Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stichting Sanquin Bloedvoorziening
Original Assignee
Stichting Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Sanquin Bloedvoorziening filed Critical Stichting Sanquin Bloedvoorziening
Application granted granted Critical
Publication of ES2152953T3 publication Critical patent/ES2152953T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6481—Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

METODOS PARA LA GENERACION DE ANTICUERPOS CA2+ INDEPENDIENTES, CONTRA FACTORES DE COAGULACION SANGUINEA, EMPLEANDO ESTRATEGIA DE SELECCION DE ANTICUERPOS, BASADA EN PEQUEÑOS PEPTIDOS QUE ESTAN COMPRENDIENDO SECUENCIAS OBJETIVO PARA PROTEOLISIS LIMITADA. ESTOS ANTICUERPOS, QUE SUSTANCIALMENTE SE DISTINGUEN ENTRE ESPECIES INTACTAS Y SEGMENTADAS DE LA CITADA PROTEINA HEMOSTATICA, PROPORCIONAN MEDIOS NUEVOS PARA EL AISLAMIENTO DE PROTEINAS HEMOSTATICAS INTACTAS. DEBIDO A LA AUSENCIA DE PRODUCTOS DE SEGMENTACION, QUE USUALMENTE SE ASOCIAN CON EFECTOS SECUNDARIOS O EFICACIA REDUCIDA, ESTAS PROTEINAS INTACTAS PUEDEN SERVIR COMO AGENTES DE PERFECCIONAMIENTO EN COMPOSICIONES TERAPEUTICAS PARA EL TRATAMIENTO DE TRASTORNOS HEMOSTATICOS.
ES93921129T 1992-08-27 1993-08-26 Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina. Expired - Lifetime ES2152953T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92202615 1992-08-27

Publications (1)

Publication Number Publication Date
ES2152953T3 true ES2152953T3 (es) 2001-02-16

Family

ID=8210886

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93921129T Expired - Lifetime ES2152953T3 (es) 1992-08-27 1993-08-26 Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina.

Country Status (12)

Country Link
US (2) US5932706A (es)
EP (1) EP0658168B1 (es)
JP (1) JP3735112B2 (es)
AT (1) ATE197590T1 (es)
AU (1) AU678987B2 (es)
CA (1) CA2143125C (es)
DE (1) DE69329682T2 (es)
DK (1) DK0658168T3 (es)
ES (1) ES2152953T3 (es)
GR (1) GR3035391T3 (es)
PT (1) PT658168E (es)
WO (1) WO1994005692A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US7109170B2 (en) * 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
US6624289B1 (en) * 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
WO2001070763A1 (en) * 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
PT1517698E (pt) 2002-06-21 2014-11-19 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
KR20060015574A (ko) 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
FR2863616A1 (fr) * 2003-12-12 2005-06-17 Stago Diagnostica Dosage de la proteine s libre non clivee par le facteur xa et utilisation de ce dosage pour l'evaluation du potentiel de coagulation
ES2395544T3 (es) * 2004-12-23 2013-02-13 Novo Nordisk Health Care Ag Reducción del contenido de contaminantes proteínicos en composiciones que comprenden una proteína dependiente de la vitamina K de interés
ES2397851T3 (es) * 2005-07-13 2013-03-11 Novo Nordisk Health Care Ag Células de inactivación proteínica de la célula huésped para la producción de proteínas terapéuticas
MX336728B (es) 2010-04-29 2016-01-27 Baxter Int Metodo de purificacion para proteinas de union de cation divalente en resina de intercambio anionico.
AU2012322948B2 (en) * 2011-10-14 2014-11-06 Takeda Pharmaceutical Company Limited Protein purification by anion exchange chromatography
JP6117219B2 (ja) 2011-10-14 2017-04-19 バクスアルタ ゲーエムベーハー 陰イオン交換クロマトグラフィによるタンパク質の精製方法
WO2014140289A1 (en) 2013-03-15 2014-09-18 Baxter International Inc. Purification method for vitamin k dependent proteins by anion exchange chromatography
EP3577140A1 (en) 2017-02-01 2019-12-11 Novo Nordisk A/S Procoagulant antibodies
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
WO2021226245A1 (en) 2020-05-05 2021-11-11 Vega Therapeutics, Inc. Protein s antibodies, methods of making and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252712A (en) * 1980-10-20 1993-10-12 New England Medical Center Hospitals, Inc. Purified antibodies which specifically bind human abnormal prothrombin
US5055557A (en) * 1983-03-04 1991-10-08 Scripps Clinic & Research Foundation Ultrapurification of factor IX and other vitamin K-dependent proteins
US4637932A (en) * 1984-10-15 1987-01-20 Miles Laboratories, Inc. Process for producing a concentrate enriched in coagulation factors VII and VIIa
EP0229026B1 (en) * 1986-01-06 1995-11-22 Blood Systems Inc, an Arizona not-for-profit corporation Therapeutic blood product, means and methods of preparing same
DE3740520A1 (de) * 1987-11-30 1989-06-08 Hans Dr Rer Nat Scheefers Schnelles verfahren zur gewinnung einer faktor vii - praeparation sowie ihre verwendung
FI86339C (fi) * 1988-12-09 1992-08-10 Ari Tuomi Diffusionscell foer undersoekning av salvor och liknande.
CA2006684C (en) * 1988-12-30 1996-12-17 Charles T. Esmon Monoclonal antibody against protein c
US5202253A (en) * 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
AT402153B (de) * 1989-06-26 1997-02-25 Immuno Ag Protein-s-hältige pharmazeutische präparation
ATE195877T1 (de) * 1991-03-01 2000-09-15 Rhone Poulenc Rorer Int Herstellung von faktor-ix
DE4329517C2 (de) * 1993-08-30 1996-04-04 Schuelke & Mayr Gmbh Waschende Händedesinfektions- und Händedekontaminationsmittel auf Basis naturidentischer, aromatischer Alkohole
AU674586B2 (en) * 1994-07-27 1997-01-02 Rain Bird Sprinkler Manufacturing Corporation Speed controlled rotating sprinkler

Also Published As

Publication number Publication date
EP0658168A1 (en) 1995-06-21
JP3735112B2 (ja) 2006-01-18
AU678987B2 (en) 1997-06-19
WO1994005692A1 (en) 1994-03-17
CA2143125A1 (en) 1994-03-17
DE69329682D1 (de) 2000-12-21
AU4835993A (en) 1994-03-29
DE69329682T2 (de) 2001-05-17
USRE38202E1 (en) 2003-07-22
PT658168E (pt) 2001-04-30
ATE197590T1 (de) 2000-12-15
GR3035391T3 (en) 2001-05-31
US5932706A (en) 1999-08-03
EP0658168B1 (en) 2000-11-15
JPH08500833A (ja) 1996-01-30
CA2143125C (en) 2008-09-23
DK0658168T3 (da) 2001-01-22

Similar Documents

Publication Publication Date Title
ES2152953T3 (es) Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina.
DK532284A (da) Fremgangsmaade til bestemmelse af antigenaktive aminosyresekvenser
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
ATE177754T1 (de) Fragmente von prion proteinen.
WO1996040885A3 (en) β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION
DE69813212D1 (de) Verfahren zur erzeugung von proteinhydrolysaten
ATE197307T1 (de) Neuroaktive peptide
EP1264890A3 (en) Plasmodium vivax blood stage antigens, antibodies, and diagnostic assays
AU6532190A (en) Carrier for binding antiphospholipid antibody, immunoassay using the same, and kit therefor
FR2816410B1 (fr) Necessaire de detection de la proteine esm-1 et procede de detection mettant en oeuvre ledit necessaire
GR3018371T3 (en) Method for identifying or determining proteins and applications therefor.
ES2072490T3 (es) Procedimiento para la pasteurizacion de la proteina tisular pp4.
DK0909388T3 (da) Immunologisk assay til spongiforme encephalopatier
MÜLLER‐ESTERL et al. Limited proteolysis of human low‐molecular‐mass kininogen by tissue kallikrein: Isolation and characterization of the heavy and the light chains
ID19063A (id) Pereaksi peptida untuk deteksi cytomegalovirus (cmv)
AU612683B2 (en) Synthetic peptides, antibodies directed against them, and the use thereof
DE69621837D1 (de) Methoden zur feststellung von alzheimerscher krankheit
AU3563397A (en) Methods for determining the presence of brain protein s-100
DK0607425T3 (da) Epstein-Barr-viruspeptider og antistoffer mod disse peptider
AR002004A1 (es) Proteina slam, anticuerpo o un fragmento del mismo que se fija a dicha proteina, metodo de purificacion, acido nucleico que codifica dicha proteina,vector de expresion, equipo que la contiene, metodo de deteccion, metodo de modulacion y metodo para preparar una composicion farmaceutica.
Srinivas et al. Translocation of plasminogen activator inhibitor-1 during serum stimulated growth of mouse embryo fibroblasts
ATE301674T1 (de) Verfahren zur trennung und bestimmung von hydrophoben proteinen durch dünnschichtchromatographie
Li et al. Cross reactivities of monoclonal antibodies against hemorrhagic toxins of Prairie rattlesnake (Crotalus viridis viridis) venom
MX9602274A (es) Procedimiento para la preservacion de antigenos sin usar inhibidores enzimaticos y su aplicacion en metodos inmunologicos.
ATE8411T1 (de) Verfahren zur spezifischen abspaltung von proteinsequenzen aus proteinen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 658168

Country of ref document: ES